"Medicare Part D" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A stand-alone drug plan offered by insurers and other private companies to beneficiaries that receive their Medicare Part A and/or B benefits through the Original Medicare Plan. It includes Medicare Private Fee-for-Service Plans that do not offer prescription drug coverage and Medicare Cost Plans offering Medicare prescription drug coverage. The plan was enacted as the Medicare Prescription Drug, Improvement and Modernization Act of 2003 with coverage beginning January 1, 2006.
Below are MeSH descriptors whose meaning is more general than "Medicare Part D".
Below are MeSH descriptors whose meaning is more specific than "Medicare Part D".
This graph shows the total number of publications written about "Medicare Part D" by people in this website by year, and whether "Medicare Part D" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Medicare Part D" by people in Profiles.
Medicare Part D Coverage of Antiobesity Medications - Challenges and Uncertainty Ahead. N Engl J Med. 2023 Mar 16; 388(11):961-963.
Promotional Payments to Medical Oncologists and Urologists and Prescriptions for Abiraterone and Enzalutamide. Urology. 2022 03; 161:50-58.
Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer. Cancer. 2020 12 01; 126(23):5050-5059.
The Receipt of Industry Payments is Associated With Prescribing Promoted Alpha-blockers and Overactive Bladder Medications. Urology. 2018 Jul; 117:50-56.
Transplant recipients are vulnerable to coverage denial under Medicare Part D. Am J Transplant. 2018 06; 18(6):1502-1509.
Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending. JAMA Intern Med. 2017 08 01; 177(8):1185-1188.
Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D. J Oncol Pract. 2017 08; 13(8):e694-e702.
Rising Prices of Targeted Oral Anticancer Medications and Associated Financial Burden on Medicare Beneficiaries. J Clin Oncol. 2017 Aug 01; 35(22):2482-2489.
National trends in spending on and use of oral oncologics, first quarter 2006 through third quarter 2011. Health Aff (Millwood). 2014 Oct; 33(10):1721-7.
Socioeconomic characteristics of enrollees appear to influence performance scores for medicare part D contractors. Health Aff (Millwood). 2014 Jan; 33(1):140-6.